// App-Quantinova.ai

SAT0324 (2018) : Certolizumab pegol provides sustained remission and minimal disease activity in patients with psoriatic arthritis over 4 years’ treatment

Researchers

Presenter

  • D. van der Heijde

Principal Investigators

  • A. Deodhar

  • O. FitzGerald

  • R. Fleischmann

  • D. Gladman

  • A.B. Gottlieb

  • L.C. Coates

  • B. Hoepken

  • L. Bauer

  • L. Peterson

  • M. Khraishi

  • P.J. Mease

Medical Centers

  • Leiden University Medical Centre, Leiden, Netherlands

  • Oregon Health and Science University, Portland, OR

  • St. Vincent's University Hospital and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland

  • The University of Texas Southwestern Medical Center, Dallas, TX

  • Centre for Prognosis Studies in The Rheumatic Diseases and Krembil Research Institute, Toronto Western Hospital, Toronto, Canada

  • Department of Dermatology, New York Medical College, Metropolitan Hospital, New York, NY

  • Nuffield Orthopaedic Centre, Oxford, UK

  • UCB Pharma, Monheim, Germany

  • UCB Pharma, Raleigh, NC

  • Faculty of Medicine, Memorial University of Newfoundland, St. Johns, NF, Canada

  • Swedish Medical Center and University of Washington School of Medicine, Seattle, WA

Locations

  • Netherlands

  • United States

  • Ireland

  • Canada

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • Malondialdehyde

Drug/Treatment

  • Certolizumab pegol

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Open Label

  • Controlled

Phase

  • NA

Study Id's

  • NCT01087788

Sponsors

  • UCB

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved